

Press Release

**LABOMAR: 2023 FINANCIAL CALENDAR**

Istrana (TV), January 13, 2023 - Labomar (Ticker: LBM), an Italian-based international nutraceutical enterprise and listed on the Euronext Growth Milan market, hereby notifies the calendar of corporate events for the year 2023.


<b>Date</b>	<b>Event</b>
26 January 2023	Consolidated Revenues Labomar Group FY2022 – Preliminary figures
29 March 2023	Board of Directors' meeting to approve the separate Financial Statements of the Company and the Consolidated Statements of the Group for the year ended December 31, 2022
20 April 2023	Consolidated Revenues Labomar Group 1Q2023 – Preliminary figures
28 April 2023	First call for the shareholders' meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2022
4 May 2023	Second call for the shareholders' meeting to approve the Separate Financial Statements of the Company and present the Consolidated Statements of the Group for the year ended December 31, 2022
20 July 2023	Consolidated Revenues Labomar Group H12023 – Preliminary figures
28 September 2023	Board of Directors' meeting to approve the Consolidated half-year report as 30 June, 2023
19 October 2023	Consolidated Revenues Labomar Group 3Q2023 – Preliminary figures

The Company will promptly notify the market of any changes to the above.

The corporate events calendar is available to the public on the website [www.labomar.com](http://www.labomar.com), in the section "[Investor - Calendar](#)"

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a



particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020.

Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research S.r.l., producers of medical devices for skincare, with its registered office in Orvieto. LaboVar S.r.l. was also established - 51% owned by Labomar - for the sale of nutraceutical products on an e-commerce platform on the Chinese market. Labomar then acquired full control of Labiotre S.r.l., a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

***For further information:***

***Labomar Press Office***

*Thanai Bernardini - +39.335.7245418 - [me@thanai.it](mailto:me@thanai.it)*

*Alessandro Bozzi Valenti - +39.348.0090866 - [alessandro.valenti@thanai.it](mailto:alessandro.valenti@thanai.it)*

***Investor Relations Labomar***

*Claudio De Nadai - +39.0422.677203 - [claudio.denadai@labomar.com](mailto:claudio.denadai@labomar.com)*

*Mara Di Giorgio - +39 335.7737417 - [mara@twin.services](mailto:mara@twin.services)*

***Euronext Growth Advisor***

*Banca Mediolanum - +39 02 9049 2525 - [ecm@mediolanum.it](mailto:ecm@mediolanum.it)*